NYSE:BSX (USA) Also Trade In: Austria Brazil Germany Mexico UK

Boston Scientific Corp $ 38.48 -1.19 (-3%)

On watch
Avg Vol (1m):
Market Cap $:
55.05 Bil
Enterprise Value $:
63.12 Bil
P/E (TTM):
Warning! GuruFocus has detected 3 Severe warning signs with BSX. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

BSX News and Headlines - Boston Scientific Corp

GuruFocus Articles Total 109
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

Amazon, Netflix, Alphabet, Facebook among largest sales

Andreas Halvorsen (Trades, Portfolio)'s Viking Global Investors manages a $23.14 billion equity portfolio composed of 71 stocks as of the quarter's end. The firm sold shares of the following stocks during the second quarter of 2020.


The fund trimmed its position in Netflix Inc. (NFLX) by 86.59%. The trade had an impact of -4.5% on the portfolio.



The streaming company has a market cap of $215 billion and an enterprise value of $223 billion.

GuruFocus gives the company a profitability and growth rating of 8

105 Views    Tiziano Frateschi    2020-08-10 19:51
Guru stock highlight

Boston Scientific (BSX) makes medical supplies and devices used to diagnose and treat various medical conditions. We eliminated the position in May on concerns that elective device procedures could be postponed or cancelled because of the COVID-19 outbreak.

From [url=https://www.gurufocus.com/StockBuy.php?GuruName=Spiros+Segalas]Spiros Segalas[/url] ([url=https://www.gurufocus.com/StockBuy.php?GuruName=Spiros+Segalas]Trades[/url], [url=https://www.gurufocus.com/holdings.php?GuruName=Spiros+Segalas]Portfolio[/url])' Harbor Capital Appreciation Fund second-quarter 2020 commentary.

21 Views    Sydnee Gatewood    2020-07-30 20:45
Visa and Cigna make the list

Andreas Halvorsen (Trades, Portfolio)’s Viking Global Investors bought shares of the following stocks in both the fourth quarter of 2019 and the first quarter of 2020.


The firm raised the Assurant Inc. (AIZ) position by 31.64% in the fourth quarter and then added 15.43% in the first quarter. The stock has a weight of 1.16% in the portfolio.

The company, which operates in the insurance industry, has a market cap of $6.23 billion. Its revenue of $10.20 billion has risen 0.90% over the last five years.


Halvorsen is the

119 Views    Tiziano Frateschi    2020-05-29 16:13
For those who can come to terms with its debt load, this medical device company offers a strong upside

What stocks are most popular among the gurus, the investing giants after whom GuruFocus is named?

To find out, we can turn to the S&P 500 Screener, which lays out where they have committed their money recently. In mid-May 2020, the top position was held by National Oilwell Varco (NOV); moving down the list to the number four position, we find Boston Scientific Corp. (BSX).

According to its 10-K for 2019, Boston Scientific is “a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.” It sells

555 Views    Robert Abbott    2020-05-19 19:01
Boston Scientific and Fidelity National make the list

David Carlson (Trades, Portfolio)’s Elfun Trusts bought shares of the following stocks in both the fourth quarter of 2019 and the first quarter of 2020.

Fidelity National

The guru raised the Fidelity National Information Services Inc. (FIS) position by 46.2% in the fourth quarter and then added 5.01% in the first quarter. The stock has a weight of 2.19% in the portfolio.

The company, which provides core and payment processing services to banks, has a market cap of $84.24 billion. Its revenue of $11.35 billion has risen 1.30% over the last five years.


164 Views    Tiziano Frateschi    2020-05-19 16:16
Third Point's top 3 sells for the quarter outweigh its top 2 new buys

Daniel Loeb (Trades, Portfolio), manager of Third Point, LLC, disclosed last week that his firm exited its positions in Campbell Soup Co. (CPB) and Boston Scientific Corp. (BSX) during the first quarter. The two transactions, plus the reduction in Baxter International Inc. (BAX), impacted the equity portfolio more than the top two new buys in Walt Disney Co. (DIS) and Charter Communications Inc. (CHTR) did.

Managing a portfolio of 32 stocks, Loeb seeks long-term capital through an event-driven, value-oriented investment style. The investor seeks situations in which a catalyst has potential to unlock value.


236 Views    James Li    2020-05-18 22:26
Firm's largest sales of the 1st quarter

Daniel Loeb (Trades, Portfolio)’s Third Point LLC sold shares of the following stocks during the first quarter of 2020.

Campbell Soup

The firm exited its Campbell Soup Co. (CPB) position. The trade had an impact of -8.18% on the portfolio.


The supplier of well-known soup and other convenience food, has a market cap of $15.73 billion and an enterprise value of $21.49 billion.

GuruFocus gives the company a profitability and growth rating of 8 out of 10. The return on equity of 98.87% and return on assets of 11.03% are outperforming

81 Views    Tiziano Frateschi    2020-05-18 18:49
Boston Scientific tops the list

Investors looking for growth opportunities may want to have a look at the following stocks, as they have a price-earnings ratio below 20 and their trailing 12-month earnings per share have grown.

Boston Scientific

The first stock to have a look at is Boston Scientific Corp. (BSX).

The Marlborough, Massachusetts-based global manufacturer and marketer of medical devices saw its trailing 12-month earnings per diluted share grow by 137.5% over the past year to $3.04 as of the quarter ended March 30, 2020, up from $1.28 in the prior-year quarter. The price-earnings ratio stands at 11.26 as of April 30.


218 Views    Alberto Abaterusso    2020-05-01 14:27
With hospitals devoting nearly all their efforts to deal with the pandemic, elective procedures are being put on the backburner

In a recent GuruFocus article, I noted that health insurers seem to be benefitting from fewer elective procedures as resources are diverted to Covid-19 care.

The same trend is having an opposite impact on medical device companies and their share prices. The pain could worsen depending on long it takes for elective surgeries to resume, even on a limited basis.

The effect of the surgery drought was driven home when industry-giant Medtronic (MDT) reported on April 20 that weekly revenue from the United States had dropped by 60% year-over-year since mid-March.

The problem has been further exacerbated as Medtronic

68 Views    Barry Cohen    2020-04-29 14:15
Viking Partners leader makes real-time pick in biotech IPO

Andreas Halvorsen (Trades, Portfolio), founding partner and chief investment officer of Viking Partners, disclosed this week his firm established a stake in Zentalis Pharmaceuticals LLC (ZNTL) according to GuruFocus Real-Time Picks, a Premium feature.

Prior to starting Viking, Halvorsen worked as senior managing director and equities director at Julian Robertson (Trades, Portfolio)’s Tiger Management. According to its website, Viking employs a research-intensive, long-term-focused investing approach. The Greenwich, Connecticut-based firm invests in companies based on a thorough assessment of the business models and fundamentals of companies, the quality of management teams and the trends

171 Views    James Li    2020-04-15 19:47
Guru releases 1st-quarter portfolio

Spiros Segalas (Trades, Portfolio), manager of the Harbor Capital Appreciation Fund, disclosed five new positions when he released his first-quarter portfolio earlier this week.

Part of Chicago-based Harbor Funds, the guru’s fund primarily invests in companies with market caps of at least $1 billion at the time of purchase. He focuses on companies that have strong balance sheets and earnings performance, good sales momentum and growth outlook, a history of high profitability, a unique market position and a capable, committed management team.

Based on these criteria, Segalas established holdings in Eli Lilly & Co. (LLY), Uber Technologies

708 Views    Sydnee Gatewood    2020-03-27 18:06
The company has a reputation-based moat and a strong industry tailwind

California-based Edwards Lifesciences (EW) specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases.

The company spun off from Baxter International (BAX) in 2000 to focus on this economically attractive, rapidly growing niche. Cardiovascular disease (referred to as “CVD”) is the number-one cause of death in the world and is the top disease in terms of health care spending in nearly every country.

According to a study by the American Heart Association, nearly half of the U.S. population will have some form of CVD by 2035, compared to 41.5% in 2015. Additionally, if we look at

1287 Views    Steven Chen    2020-03-19 17:04
A crucial point on the common stock checklist by the father of growth investing

The research and development activity is like a twofer to a business. On the one hand, it may unlock additional customer value so as to widen the competitive gap against peers. On the other side, it could extend product lines or enhance operational efficiency, which would fuel organic growth.

Growth investment guru Phil Fisher considered the effectiveness of a company’s research and development efforts in relation to its size as one of the 15 primary factors that he used to evaluate a common stock. Admittedly, to gauge the return on the company’s R&D spending is neither easy nor simple. The

365 Views    Steven Chen    2020-03-18 17:06
Fund's top buy is in gold ETF. It also enters a small stake in Buffett's conglomerate

The Signature Select Canadian Fund (Trades, Portfolio) disclosed this week that its top five buys for the six months ending Sept. 30 were SPDR Gold Trust (GLD), Merck & Co. Inc. (MRK), Danone SA (XPAR:BN), Boston Scientific Corp. (BSX) and Basf SE (XTER:BAS).

The fund, which is part of CI Investments, releases its portfolio updates semiannually. Led by Chief Investment Officer Eric Bushell, Signature Select seeks long-term capital appreciation primarily through common-stock investments in Canadian companies that pay regular income. Qualitative characteristics, including company management and governance structures, play an important role in the fund’s stock selection

177 Views    James Li    2019-12-17 21:50
A near-monopoly pioneer in a fast-growing space

California-based Intuitive Surgical (ISRG) is the pioneer and a global technology leader in robotic-assisted, minimally invasive surgery, which improves clinical outcomes and experience of patients, reduces medical risks, and lowers healthcare costs. The company develops, manufactures, and markets the da Vinci surgical system and related products.

For a long time, Intuitive Surgical has been dominating the lucrative Robotic MedTech space, which is expected to grow at a 7.7% compound annual growth rate between 2018 and 2028, according to MedTech Intelligence. While competitors like Medtronic (MDT) are trying to catch up, for the time being, we are positive regarding

613 Views    Steven Chen    2019-11-29 21:16
Market value of medical device maker up nearly 30% since December

If Johnson & Johnson (JNJ) is thinking about making a run at Boston Scientific Corp. (BSX), as was rumored late last year, the New Jersey-based health care giant is going to have to dig deeper into its pockets. Boston Scientific’s market value has soared nearly 30% since last December, to nearly $60 billion.

Shareholders may want an even bigger premium after Boston Scientific painted a rosy picture for its medical device business at a recent investor day. Even though the company’s first-quarter results fell short of analysts' expectations, management said it anticipates solid revenue and earnings growth through 2022.


320 Views    Barry Cohen    2019-06-28 21:34
The medical devices producer beat consensus on earnings

Boston Scientific Corp. (BSX) reported fourth-quarter earnings before the opening bell on Wednesday.

The company posted non-GAAP earnings of 39 cents per share, beating consensus estimates by 3 cents per share, and GAAP earnings of 27 cents per share, topping estimates by 7 cents. Both firgures improved from the prior-year quarter.

The Marlborough, Massachusetts-based medical devices producer recorded $2.56 billion in revenue, reflecting a 6.2% increase year over year. The company's results were in line with analysts' expectations.

Compared to the year-ago period, Boston Scientific reported a 7.4% increase in sales from the MedSurg segment to $800 million,

31 Views    Alberto Abaterusso    2019-02-06 19:43
Boston Scientific makes the list

According to the GuruFocus All-in-One Guru Screener, the following stocks have outperformed the Standard & Poor's 500 index over the past 12 months and were bought by gurus during the third quarter.

Brown & Brown Inc. (BRO) has a market cap of $8.03 billion. It has outperformed the S&P 500 Index by 14.8% over the past 12 months.


The stock is trading with a price-book ratio of 2.68. According to the DCF calculator, the stock is overpriced by 42% at $28.31 per share. The share price is

127 Views    Tiziano Frateschi    2019-01-28 17:14
A leadership position in an industry that is virtually inflation-proof, selling at a sharp discount

Regardless of what happens in the new year, it's a safe bet that medical appliance makers like Zimmer Biomet (ZBH) will continue to thrive. Now, thanks to the fourth-quarter market sell off, Zimmer's stock is a bargain again.

Zimmer Biomet is the leader in hip and knee reconstruction products with majority share in the U.S., Japan and across Europe. With an aging baby boomer population here in the U.S. and rising global population, it will see at least a percentage of people in need of joint repair. Zimmer has built a network of close relationships with orthopedic surgeons who make

336 Views    Jonathan Poland    2018-12-28 17:18
The Swiss firm says Abbott Labs, Boston Scientific, Medtronic, Stryker, Baxter International and Edwards Lifesciences will outperform, while Zimmer Biomet will underperform

Analysts at Credit Suisse Group AG (CS) took action on large health care stocks on Tuesday.

Credit Suisse initiated coverage of Abbott Laboratories (ABT), Boston Scientific Corp. (BSX), Medtronic PLC (MDT), Stryker Corp. (SYK), Baxter International Inc. (BAX) and Edwards Lifesciences Corp. (EW) with an outperform rating.

The Swiss bank also initiated coverage of Zimmer Biomet Holdings Inc. (ZBH) with an underperform rating.

The table below shows Credit Suisse’s price target for each of the health care stocks, the percentage of upside or downside the target price represents from the closing share price on Tuesday, the average target price and

53 Views    Alberto Abaterusso    2018-12-19 19:46

Headlines Total 136
  • 1
  • 2

2020-09-15 $ 41.02 (-0.24%)
2020-09-14 $ 41.12 (2.06%)
2020-09-04 $ 41.48 (-0.02%)
2020-09-02 $ 42.23 (1.83%)
2020-08-28 $ 41.03 (0.61%)
2020-08-18 $ 39.33 (-0.05%)
2020-08-13 $ 39.75 (-0.53%)
2020-07-30 $ 38.94 (-2.19%)
2020-07-29 $ 39.81 (4.02%)
2020-07-23 $ 38.43 (0.1%)
2020-07-22 $ 38.39 (2.43%)
2020-07-15 $ 36.7 (4.2%)
2020-07-09 $ 34.5 (-0.14%)
2020-07-03 $ 35.38 (%)
2020-06-11 $ 35.05 (-6.51%)
2020-06-03 $ 37.91 (0.99%)
2020-06-02 $ 37.54 (0.11%)
2020-05-29 $ 37.99 (1.39%)
2020-05-28 $ 37.47 (0.89%)
2020-05-19 $ 35.43 (-2.72%)
2020-05-08 $ 38.18 (3.19%)
2020-05-05 $ 36.81 (2.74%)
2020-05-01 $ 35.99 (-3.98%)
2020-04-29 $ 37.43 (4.17%)
2020-04-28 $ 35.93 (-2.89%)
2020-04-24 $ 36.9 (1.37%)
2020-04-23 $ 36.4 (2.56%)
2020-04-22 $ 35.49 (1.26%)
2020-04-20 $ 37.25 (-2.72%)
2020-04-17 $ 38.29 (8.01%)
2020-04-09 $ 36.83 (4.84%)
2020-04-08 $ 35.13 (4.27%)
2020-04-03 $ 31.17 (0.39%)
2020-04-01 $ 30.19 (-7.48%)
2020-03-31 $ 31.64 (3.36%)
2020-03-30 $ 31.64 (3.36%)
2020-03-27 $ 30.61 (-2.58%)
2020-03-03 $ 37.23 (-2.72%)
2020-02-26 $ 39.39 (-1.3%)
2020-02-25 $ 39.91 (-2.85%)
2020-02-13 $ 42.18 (-0.12%)
2020-02-10 $ 42.22 (0.07%)
2019-12-16 $ 45.2 (0.24%)
2019-11-06 $ 40.72 (0.32%)
2019-10-03 $ 39.75 (1.53%)
2019-06-24 $ 42.01 (0.77%)
2019-06-21 $ 41.69 (-0.41%)
2019-06-20 $ 41.86 (0.48%)
2019-06-17 $ 40.68 (0.64%)
2019-06-13 $ 40.8 (-0.9%)
2019-06-10 $ 41.45 (0.41%)
2019-06-06 $ 40.01 (2.46%)
2019-06-04 $ 39.05 (1.98%)
2019-05-29 $ 38.45 (-0.05%)
2019-05-27 $ 38.47 (%)
2019-05-21 $ 37.29 (-0.08%)
2019-05-20 $ 37.29 (-0.08%)
2019-05-14 $ 36.76 (2.2%)
2019-05-13 $ 35.97 (-1.67%)
2019-05-09 $ 37.07 (1.01%)
2019-05-07 $ 36.77 (-1.61%)
2019-05-06 $ 37.37 (0.46%)
2019-05-03 $ 36.89 (1.4%)
2019-05-02 $ 36.89 (1.4%)
Total 136
  • 1
  • 2